Prognosia, a startup founded by WashU Medicine professors Joy Jiang and Graham Colditz, quickly advanced from research to acquisition thanks to St. Louis’s innovation ecosystem. The company’s AI software analyzes mammograms to better predict breast cancer risk, drawing early clinical interest but facing regulatory and commercialization hurdles. Biogenerator, the startup arm of BioSTL, played a pivotal role by providing seed funding, business guidance, and FDA support, helping position Prognosia for success. That groundwork led to Seoul-based Lunit acquiring the company within a year—an exit that highlights both local expertise and the importance of startup support structures in St. Louis.
